Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN)
Peptide Innovation for Early Diabetes Treatment (PIONEER)
Semaglutide Treatment Effect in People with Obesity (STEP)
Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC)
Glucagon-Like Peptide 1 receptor agonists (GLP-1Ras) has been evaluated for its several positive effects in the treatment of type 2 diabetes mellitus (T2DM). Semaglutide has both of injectable and oral formulations, which is beneficial. Three clinical trials were conducted, which are Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN), Peptide Innovation for Early diabetes treatment (PIONEER) and Semaglutide Treatment Effect in People with Obesity (STEP). Among them, satisfactory clinical effects of reducing HbA1c and body weight have been observed. Oral semaglutide, Rybelsus has been effective oral hypoglycemic agent (OHA) and seems to be more prescribed widely.
SunText Review of Endocrine Care
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|DOI (Published Version)|
|URL ( Publisher's Version )|
srec_2_1_107.pdf 374 KB